Product CAS No
Molnupiravir is an experimental antiviral medication. It is orally active. It was developed to treat influenza. It is a prodrug of synthetic nucleoside.
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans.